Last reviewed · How we verify

NCT01317966: Incritop

A Multicentre Investigation of Recombinant Human Interleukin-11 (rhIL-11) Combination Low-dose Rituximab in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)

Withdrawn Last updated 18 April 2016
What this trial tests

trial testing rhIL-11 in Purpura, Thrombocytopenic, Idiopathic. Withdrawn.

Timeline
1 March 2011
Primary endpoint
1 December 2011
1 March 2012

Quick facts

Lead sponsorMing Hou
StatusWithdrawn
Study typeOBSERVATIONAL
Start date1 March 2011
Primary completion1 December 2011
Estimated completion1 March 2012
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Ming Hou — full company profile →

Who can join

Adults 16 to 75, any sex, with Purpura, Thrombocytopenic, Idiopathic. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to determine whether Recombinant Human Interleukin-11 (rhIL-11) Combination Low-dose Rituximab prednisone are effective and safe in the management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of rhIL-11

Trials testing the same drug.

Other Ming Hou trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01317966.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing